Plain-English translation of NCT06582940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study compares two ways of delivering radiation therapy to brain tumors caused by non-small cell lung cancer that has spread to the brain. Half of patients will receive MRI-guided adaptive stereotactic radiotherapy, which uses real-time MRI imaging to precisely target tumors, while the other half will receive standard CT-guided radiation therapy. The goal is to see if the newer MRI-guided approach is just as safe and effective while potentially reducing unnecessary radiation to surrounding healthy brain tissue.
Currently, doctors add extra margin (safety buffer) around brain tumors during radiation planning to account for any movement or uncertainty. The newer MRI-guided technology allows doctors to see tumors in real-time and adjust during treatment, which might let them reduce or eliminate these safety margins and spare more healthy brain tissue from radiation.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the newer MRI-guided radiation therapy or standard CT-guided radiation therapy. Either way, you will receive the same total dose of radiation delivered over 5 days (one treatment per day). After treatment is finished, you will have regular follow-up appointments to monitor how well the treatment worked and check for any side effects. The study will track your progress over time to see how safe and effective each approach is.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China